TCGA-A2-A0EX-01A-21R-A034-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 25
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- ESTROGEN_RESPONSE_EARLY+0.370
- UV_RESPONSE_DN+0.350
- ANDROGEN_RESPONSE+0.280
- MYOGENESIS+0.280
- BILE_ACID_METABOLISM+0.270
- PEROXISOME+0.270
- ESTROGEN_RESPONSE_LATE+0.260
- FATTY_ACID_METABOLISM+0.240
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.520
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.380
- MITOTIC_SPINDLE-0.380
- GLYCOLYSIS-0.240
- IL6_JAK_STAT3_SIGNALING-0.240
- SPERMATOGENESIS-0.210
- DNA_REPAIR-0.180
- TNFA_SIGNALING_VIA_NFKB-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20060260.Her2HRpos | — | A | 0.798 |
| 2 | 563e85fb-9532-4d69-a1b5-2bc77f237b77 | — | — | 0.777 |
| 3 | TCGA-AO-A12G-01A-11R-A10J-07 | — | A | 0.774 |
| 4 | SRR1516093 | — | — | 0.763 |
| 5 | 20020054.LumA | — | A | 0.760 |
| 6 | TCGA-AR-A1AN-01A-11R-A12P-07 | — | A | 0.755 |
| 7 | MBCProject_0504_T1_RNA | — | A | 0.751 |
| 8 | TCGA-BH-A0BM-01A-11R-A056-07 | — | A | 0.748 |
| 9 | 20020070.LumA | — | A | 0.747 |
| 10 | SRR1313101 | — | A | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.490 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |